Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 June 2021Website:
http://elevationoncology.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 27 Jun 2024 23:55:35 GMTDividend
Analysts recommendations
Institutional Ownership
ELEV Latest News
-- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively -- -- Expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- Combination cohorts broaden market opportunity for EO-3021 to address unmet needs across second- and first-line gastric or gastroesophageal junction cancer settings -- -- On-track to provide update from ongoing Phase 1 clinical trial evaluating monotherapy EO-3021 by mid-3Q 2024, with additional data in 1H 2025 -- BOSTON , June 27, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced plans to expand its ongoing Phase 1 clinical trial to include two combination cohorts evaluating EO-3021 for the treatment of advanced gastric or gastroesophageal junction cancer. Following recently signed clinical supply agreements with Eli Lilly and Company (Lilly) and GSK, respectively, Elevation Oncology will evaluate EO-3021 in combination with ramucirumab, a VEGFR2 inhibitor, in second-line patients and in combination with dostarlimab, a PD-1 inhibitor, in the front-line setting.
-- Data support ongoing development of antibody-drug conjugate (ADC) program targeting HER3-expressing cancers – -- On-track to nominate development candidate in 2024 -- BOSTON , March 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical need, today announced that it will present preclinical proof-of-concept data for its differentiated HER3-targeting antibody-drug conjugate (ADC) program in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California. "We are excited to share preclinical proof-of-concept data for our HER3-ADC program.
Elevation Oncology (NASDAQ: ELEV ) stock is taking a beating on Friday after the healthcare company announced a public stock offering. That public offering of ELEV stock has the company selling 17,810,000 shares at a price of $2.25 each.
Elevation Oncology NASDAQ: ELEV is a biotech company that focuses on discovering and developing cancer therapies. The company aims to treat patients with various solid tumors with significant unmet medical needs.
Elevation Oncology (NASDAQ: ELEV ) stock is on the rise Friday despite a lack of news from the pharmaceutical company. There's no news that explains why shares of ELEV stock are taking off today.
Here is how Elevation Oncology, Inc. (ELEV) and Senesco Technologies Inc. (ELOX) have performed compared to their sector so far this year.
What type of business is Elevation Oncology?
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
What sector is Elevation Oncology in?
Elevation Oncology is in the Healthcare sector
What industry is Elevation Oncology in?
Elevation Oncology is in the Biotechnology industry
What country is Elevation Oncology from?
Elevation Oncology is headquartered in United States
When did Elevation Oncology go public?
Elevation Oncology initial public offering (IPO) was on 25 June 2021
What is Elevation Oncology website?
https://elevationoncology.com
Is Elevation Oncology in the S&P 500?
No, Elevation Oncology is not included in the S&P 500 index
Is Elevation Oncology in the NASDAQ 100?
No, Elevation Oncology is not included in the NASDAQ 100 index
Is Elevation Oncology in the Dow Jones?
No, Elevation Oncology is not included in the Dow Jones index
When does Elevation Oncology report earnings?
The next expected earnings date for Elevation Oncology is 02 August 2024